HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations.

Abstract
To elucidate whether tyrosine kinase inhibitor (TKI) resistance in chronic myeloid leukemia is associated with characteristic genomic alterations, we analyzed DNA samples from 45 TKI-resistant chronic myeloid leukemia patients with 250K single nucleotide polymorphism arrays. From 20 patients, matched serial samples of pretreatment and TKI resistance time points were available. Eleven of the 45 TKI-resistant patients had mutations of BCR-ABL1, including 2 T315I mutations. Besides known TKI resistance-associated genomic lesions, such as duplication of the BCR-ABL1 gene (n = 8) and trisomy 8 (n = 3), recurrent submicroscopic alterations, including acquired uniparental disomy, were detectable on chromosomes 1, 8, 9, 17, 19, and 22. On chromosome 22, newly acquired and recurrent deletions of the IGLC1 locus were detected in 3 patients, who had previously presented with lymphoid or myeloid blast crisis. This may support a hypothesis of TKI-induced selection of subclones differentiating into immature B-cell progenitors as a mechanism of disease progression and evasion of TKI sensitivity.
AuthorsDaniel Nowak, Seishi Ogawa, Markus Müschen, Motohiro Kato, Norihiko Kawamata, Antonie Meixel, Verena Nowak, Han S Kim, Sharon Kang, Ronald Paquette, Mi-Sook Chang, Nils H Thoennissen, Nils H Thoenissen, Max Mossner, Wolf-Karsten Hofmann, Alexander Kohlmann, Tamara Weiss, Torsten Haferlach, Claudia Haferlach, H Phillip Koeffler
JournalBlood (Blood) Vol. 115 Issue 5 Pg. 1049-53 (Feb 04 2010) ISSN: 1528-0020 [Electronic] United States
PMID19965645 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Benzamides
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Thiazoles
  • Imatinib Mesylate
  • Protein-Tyrosine Kinases
  • Fusion Proteins, bcr-abl
  • nilotinib
  • Dasatinib
Topics
  • Benzamides
  • Chromosome Aberrations
  • Chromosomes, Human, Pair 1 (genetics)
  • Chromosomes, Human, Pair 17 (genetics)
  • Chromosomes, Human, Pair 19 (genetics)
  • Chromosomes, Human, Pair 22 (genetics)
  • Chromosomes, Human, Pair 8 (genetics)
  • Chromosomes, Human, Pair 9 (genetics)
  • Dasatinib
  • Drug Resistance, Neoplasm (genetics)
  • Fusion Proteins, bcr-abl (genetics)
  • Gene Expression Profiling
  • Gene Expression Regulation, Leukemic
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy, genetics)
  • Mutation
  • Oligonucleotide Array Sequence Analysis (methods)
  • Piperazines (pharmacology, therapeutic use)
  • Polymorphism, Single Nucleotide
  • Protein Kinase Inhibitors (pharmacology, therapeutic use)
  • Protein-Tyrosine Kinases (antagonists & inhibitors, genetics)
  • Pyrimidines (pharmacology, therapeutic use)
  • Thiazoles (pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: